Sorry, you need to enable JavaScript to visit this website.

This site is intended only for healthcare professionals resident in the United Kingdom

Prescribing information can be found at the bottom of the page

Tigecycline recommended dosage regimen1

Adults1

  • The recommended dose of Tygacil is an initial dose of: 100 mg followed by 50 mg every 12 hours for 5 to 14 days
  • The duration of therapy should be guided by the severity, site of the infection, and the patient’s clinical response

Children and adolescents (8 to 17 years of age)1

  • Tygacil is only to be used to treat patients aged 8 years and older after consultation with a physician with appropriate experience in the management of infectious diseases
  • The posology for children aged 8 to <12 years is 1.2 mg/kg of Tygacil every 12 hours intravenously to a maximum dose of 50 mg every 12 hours for 5 to 14 days
  • The posology for adolescents aged 12 to <18 years is 50 mg of Tygacil every 12 hours for 5 to 14 days
  • Tygacil should not be used in children under 8 years of age due to the lack of data on safety and efficacy in this age group and because of tooth discoloration
  • Tigecycline is administered only by intravenous infusion over 30 to 60 minutes. Tigecycline should be preferably administered over a 60-minute length of infusion in paediatric patients.
  • Clinical experience in the use of Tygacil for the treatment of infections in pediatric patients aged 8 years and older is very limited. Consequently, use in children should be restricted to those clinical situations where no alternative antibacterial therapy is available

Tigecycline - dosing every 12 hours1

No dosage adjustment is necessary in1:

  • Elderly patients
  • Patients with renal impairment
  • Patients undergoing hemodialysis
  • Patients with mild-to-moderate hepatic impairment (Child-Pugh A and Child-Pugh B)†

† In patients (including pediatrics) with severe hepatic impairment (Child-Pugh C), dosage should be reduced by 50%. Patients with severe hepatic impairment (Child-Pugh C) should be treated with caution and monitored for treatment response.

 

References

  1. Tygacil Summary of Product Characteristics